Azro

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azro

What is Azro? Core Identity and Classification

Property Description
Active ingredient Azithromycin (as Azithromycin dihydrate)
Form Tablet, Capsule, Oral Suspension, Injectable Solution
Pharmacological class Macrolide Antibiotic (Azalide)
Common use Anti-infective agent for bacterial pathogens
Origin Semisynthetic compound

What Type of Medicine is Azro (Azithromycin)?

Azro is a trade name for a prescription-only medicine whose active substance is Azithromycin, a semisynthetic compound classified as a macrolide antibiotic and specifically belonging to the Azalide subgroup. The drug substance is commonly present as Azithromycin dihydrate, which is an anti-infective agent used for systemic administration against susceptible bacterial pathogens. The unique chemical structure of the Azalide subgroup differentiates it from older macrolides, providing enhanced stability and absorption.

Azithromycin is clinically recognized for achieving high concentrations in body tissues, a factor which contributes to its long elimination half-life and allows for shorter or once-daily dosing compared to many other antibiotics. This confirms that the medicine maintains a sustained antibacterial agent effect within the body over time.


Composition, Origin, and Available Forms

Azithromycin is formulated as a single-active-ingredient product and is available in multiple pharmaceutical preparations to accommodate different treatment needs and route of administration requirements. The medication is commonly supplied in oral formats, including the tablet, capsule, and oral suspension, designed for convenient systemic administration. The availability of the oral suspension is particularly relevant for the pediatric patient group, enabling flexible dosing for children.

In addition to oral forms, the antibacterial agent is manufactured as an injectable solution for acute care and an ophthalmic solution for targeted topical application. These preparations consist of the active ingredient combined with necessary pharmaceutical excipients to ensure drug stability and proper delivery to the site of action.


What is the General Purpose of This Antibacterial Agent?

The general purpose of Azithromycin is to neutralize or control the growth of susceptible bacterial pathogens. It is designed to act by binding to the bacterial 50S ribosomal subunit to disrupt bacterial protein synthesis, which is the fundamental process bacteria rely on for growth and replication. By executing this function, Azithromycin serves as a foundational therapeutic tool for treating bacterial infections, such as those affecting the respiratory tract.

Because of its broad-spectrum activity and clinically confirmed utility, macrolides like Azithromycin are classified as essential medicines globally. This medicine is considered a critical tool in public health for managing infections caused by bacteria.

What side effects are possible with Azro?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse reactions associated with Azithromycin (Azro) into frequency categories and by the body systems they affect. This framework structures the official safety profile of the medicine.

Adverse Reaction Classification

Adverse effects are documented using a frequency framework, ranging from Very Common (occurring in 1 in 10 patients or more, such as diarrhea with certain formulations) to Common (e.g., abdominal pain, nausea, headache, vomiting). Effects classified as Uncommon include flatulence, rash, and specific blood cell count changes. Rare documented events, such as specific cardiovascular effects like Torsades de Pointes, and cholestatic jaundice, are also officially listed.

Reactions are grouped into System-Organ Classes, including Gastrointestinal Disorders, Hepatobiliary Disorders, Cardiac Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Constraints

The regulatory label highlights specific reactions as serious due to their clinical significance. These include the potential for Prolongation of the QT interval, which carries a risk for severe arrhythmia; cases of Fatal Hepatic Failure and liver necrosis; and Serious Dermatologic Reactions like Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Clostridioides difficile-associated diarrhea (CDAD) is also a documented risk that may occur even two months after treatment discontinuation. Safety constraints limit the use of Azro in individuals with a known hypersensitivity to the macrolide class or a history of jaundice linked to prior Azithromycin use. Caution is advised for patients with pre-existing proarrhythmic cardiac conditions or severe hepatic or renal impairment.

Overdose and Emergency Response

The regulatory profile for Azithromycin (Azro) overdose is strictly defined by the potential for severe, extended adverse effects and the high risk of serious cardiovascular complications. Documented clinical manifestations of an overdose, often resulting from higher than recommended doses, are typically reported as severe nausea, vomiting, and diarrhoea, which are intensified versions of common side effects. Reversible hearing loss has also been noted in overdose scenarios.

The most critical concern documented in official prescribing information is the potential for prolongation of the QT interval. This can lead to the development of Torsades de Pointes and other potentially fatal cardiac arrhythmias. Due to this life-threatening risk, individuals must seek immediate medical attention in all suspected overdose situations.

Regulatory agencies mandate that management relies on general symptomatic and supportive measures. It is officially stated that no specific antidote is known for Azithromycin toxicity. Procedures may involve the administration of medicinal charcoal to limit absorption. Continuous observation and hospital monitoring are necessary to assess and manage the severe cardiac risks, particularly in elderly patients and individuals with pre-existing proarrhythmic conditions who face an elevated risk of severe outcomes.

Therapeutic Uses of Azro

What Azro Treats: Main Uses and Benefits

Azro contains the active ingredient azithromycin, which is an antibiotic generally used for the management of bacterial infections.

It is indicated for the management of mild to moderate conditions caused by designated, susceptible bacteria. These conditions involve a range of symptoms related to localized or systemic discomfort and often require symptomatic assistance.

The medicine is relevant for easing symptoms associated with acute episodes, such as:

  • Respiratory Tract Infections, like community-acquired pneumonia, acute bacterial sinusitis, or exacerbations of chronic bronchitis;
  • Skin and Skin Structure Infections; and
  • Certain Sexually Transmitted Diseases.

In these clinical scenarios, Azro supports general well-being during symptomatic phases. It is commonly used when symptoms intensify and supportive relief is needed. This therapeutic use assists with maintaining functional stability by addressing symptom clusters that may become intense or disruptive.

“This class of antibiotics is applied across domains where additional symptomatic support is needed, helping ease the overall symptom burden.”


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Who can and cannot use Azro?

Azro (Azithromycin) eligibility is defined by official regulatory documents, establishing clear rules for populations allowed, restricted, or absolutely prohibited from use.


Absolute Contraindications

Azro must not be used in patients with a known hypersensitivity to azithromycin, erythromycin, or any macrolide/ketolide antibiotic. Use is also prohibited in individuals with a documented history of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin treatment.

Age-Related Eligibility

Azro is approved for adults and pediatric patients 6 months of age and older. Safety and effectiveness have not been established for most uses in children under 6 months. Use in neonates carries a specific warning regarding Infantile Hypertrophic Pyloric Stenosis (IHPS).

Conditional Use and Restrictions

Use requires caution in several patient groups, including those with severe renal impairment (GFR < 10 mL/min) and patients with pre-existing proarrhythmic conditions such as known QT prolongation or a history of Torsades de Pointes. Caution is also advised for patients with severe hepatic impairment and those with Myasthenia Gravis.

Pregnancy and Lactation Status

The medicine should be used during pregnancy only if clearly needed, and caution should be exercised when administering to nursing mothers.

What should I know about interactions with other medicines?

Azro (azithromycin) has formally documented interaction patterns that regulate its co-administration with other substances. A primary restriction involves a prohibition on co-administration with Ergot Derivatives, such as ergotamine, due to the theoretical potential for ergotism, a serious class-specific toxicity documented in regulatory sources.

The official profile outlines key pharmacodynamic constraints regarding cardiac risk. Co-administration with agents known to prolong the QT interval (e.g., specific antiarrhythmics or certain antipsychotics) creates a documented additive effect, increasing the risk for ventricular arrhythmias.

Pharmacokinetic interactions are also defined. Azithromycin is officially documented to inhibit P-glycoprotein, which can lead to an increase in the serum levels of transporter substrates like Digoxin. Co-administration with the HIV protease inhibitor Nelfinavir significantly raises the plasma exposure of Azithromycin itself. When co-administered with Warfarin, the potential for increased coagulation times is documented, necessitating procedural monitoring.

For oral administration, certain Antacids containing aluminum or magnesium reduce the peak concentration of Azithromycin. This interaction requires a mandatory timing separation, meaning Azithromycin must be administered at least 1 hour before or 2 hours after the antacid dose. Regulatory documents also note that Azithromycin does not participate in the significant CYP450 enzyme inhibition common to other macrolides.

Mechanism of Action

The mechanism of action for Azro, whose active substance is Azithromycin, is defined by two primary mechanistic domains that result in distinct physiological changes. The drug functions through Blockade of Bacterial Protein Synthesis and Modulation of Host Inflammatory Pathways.

Inhibition of Bacterial Protein Synthesis

This core mechanism involves Azithromycin acting as a non-competitive inhibitor by binding specifically to the 23S rRNA within the bacterial 50S ribosomal subunit. This physical blockade of the peptide exit tunnel stops the translocation process, preventing the synthesis of essential proteins and resulting in the arrest of bacterial growth and replication.

Modulation of Host Inflammatory Response

Beyond its effect on bacteria, Azithromycin functions as an immunomodulator within host tissues. It affects the signaling of immune cells, notably by suppressing the activity of the transcription factor NF-kappaB. This action limits the production and release of pro-inflammatory cytokines. The resulting effect on cytokine release is the downregulation of localized tissue inflammation and a reduction in the activation state of specific host immune pathways.

Dosage and Administration Information

How to Use Azro: Official Administration Guidelines

The principles for using Azro (Azithromycin) are established to govern its route, dose, and frequency. The medicine is authorized for both oral administration (tablets, capsules, and suspension) and intravenous (IV) administration.

Official Dosing and Frequency

Most common adult regimens follow a once-daily pattern, reflecting the long duration of action of the active ingredient. Treatment courses are defined by the total dose and duration, which typically span three to five days for standard infections. Specific high-dose regimens, such as 1000 mg or 2000 mg, are administered as a single oral dose for certain conditions. Long-term use for specific prophylaxis is prescribed as 1200 mg taken once weekly.

For initial therapy of certain severe infections, Azro is administered via the IV route at 500 mg once daily, which is followed by a transition to oral therapy to complete the overall course (sequential therapy).

Contextual Use and Procedural Rules

Instruction Domain Official Requirement
Food Intake Tablets and standard suspensions may be taken with or without food, but specific capsule or extended-release forms must be taken on an empty stomach (1 hour before or 2 hours after a meal).
IV Administration The injectable solution requires reconstitution and dilution and must be infused slowly over 1 to 3 hours. It is prohibited to administer the IV solution as a rapid bolus or intramuscular injection.
Pediatric Dosing Dosing for children (ge 6 months) is typically determined by patient weight, not to exceed the adult dose.

If a dose is missed, the general practice is to take the dose immediately upon remembering and then resume the standard scheduled time for the subsequent doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azro (Azithromycin)

The research foundation for Azro (azithromycin) consists primarily of Randomized Controlled Trials (RCTs), which compare the medicine against either inactive treatments or other commonly studied regimens, alongside systematic reviews that analyze the combined data. These studies are relevant for understanding how symptoms are measured and how conditions evolve in the populations observed.


Evidence for Use in Acute Respiratory and Skin Infections

Azro was studied extensively in research exploring how symptoms change over time for acute bacterial infections affecting the lungs, airways, and skin. These studies were generally conducted during periods of increased symptom activity. For conditions like community-acquired pneumonia and acute exacerbations of chronic bronchitis, research examined short-term changes in patient health. Studies monitored outcomes related to physical discomfort, and findings describe patterns observed in the studies, with measurements taken shortly after the end of the treatment course. In the context of uncomplicated skin and skin structure infections, studies report how symptoms evolved in the observed populations, and the evidence describes symptom patterns over a defined, short time interval.

Evidence for Use in Certain Sexually Transmitted Infections

Azro was studied for specific uncomplicated infections caused by certain susceptible organisms like Chlamydia trachomatis. The research included comparative trials where Azro was studied alongside other commonly used antibiotic regimens. Studies explored microbiological outcomes, meaning researchers focused on whether the specific bacterial pathogen was detected after administration. Findings indicate patterns where Azro's short-course regimen was studied to measure the presence of the pathogen. The evidence remains limited for other related infections, as comparative research for those is often lacking.

What Remains Uncertain in the Evidence Base

Scientific review highlights several areas where the evidence is still emerging or where certainty remains low. One key limitation is that sample sizes were modest in some specific sub-analyses, and the evidence quality varies across studies when looking at highly specific groups. Furthermore, observational settings have shown that Azro was associated with a rare, temporary increase in acute cardiovascular events in some high-risk adult populations compared to certain other antibiotics. While this pattern was observed in some studies, the research findings exploring short-term outcomes related to systemic imbalance were mixed. Regulatory oversight emphasizes that research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Azro (FAQ)


Q: Does Azro make you tired or drowsy?

A: Regulatory safety information indicates that both fatigue (tiredness) and somnolence (drowsiness) are listed among the adverse reactions reported during postmarketing use of the drug. If these effects are experienced, it is generally noted that caution should be exercised regarding activities requiring alertness.

Q: Is it normal to feel a change within the first week of taking Azro?

A: Azro is frequently prescribed as a short treatment course, often lasting only three to five days. This is supported by the fact that the active ingredient has a long elimination half-life and quickly achieves sustained, high concentrations in body tissues. This pharmacological property is consistent with its short duration of therapy.

Q: Can Azro be taken with a multivitamin?

A: Official regulatory documents and health sources advise a general caution regarding the co-administration of Azro with all supplements, including multivitamins. Since specific interaction testing is not available for all products, patients should discuss them with a healthcare provider.

Q: Does Azro affect how birth control pills work?

A: Official product information suggests that Azro is generally less likely to interact with oral contraceptives than some other macrolide antibiotics. Patients are always advised to consult a healthcare provider for confirmation about specific birth control methods and products.

Q: Q: What happens if I forget to take Azro for a few days?

A: Official instructions specifically address how to manage a single missed dose, which is to take it immediately and then resume the standard schedule. Because of the drug’s long duration of action, missing multiple doses is not covered by this standard guidance, and consultation with a healthcare professional is generally appropriate.

Q: Are the side effects of Azro permanent?

A: Most common side effects, such as stomach upset, are generally reversible after the medication is stopped. However, official safety documentation is required to list all serious adverse reactions (like rare liver or cardiac events) due to their clinical significance, even if they are infrequent.

Q: Is it true that Azro takes several weeks to start working?

A: This statement is generally not supported by the official recommended treatment plan. Azro is typically prescribed for a short course, meaning it is intended to reach therapeutic concentrations in body tissues quickly to start addressing the infection.

Q: Does Azro interact with herbal supplements like St. John's Wort?

A: Official regulatory information does not provide specific data on the interaction between Azro and many herbal supplements, including St. John’s Wort. As with all concurrent medicines and supplements, patients should discuss their use with a healthcare provider.

Q: Will Azro affect my ability to drive or operate machinery?

A: Official safety documents list nervous system adverse reactions such as dizziness, vertigo, and somnolence (drowsiness). Patients who experience these side effects are cautioned regarding activities that require full mental alertness, such as driving or operating machinery.

Q: Can Azro make you feel anxious or moody?

A: Regulatory documents list specific psychiatric reactions, including anxiety and aggressive reaction, among the adverse effects reported during postmarketing use. If these or other mood changes are experienced, consultation with a healthcare provider is generally recommended.

Q: Does alcohol interact negatively with Azro?

A: There is no specific contraindication with alcohol listed in the core regulatory documents. However, official health sources generally suggest avoiding alcohol while on this medication if you experience side effects like nausea or dizziness, as alcohol may worsen them.

Q: Can Azro affect sleep patterns?

A: Official safety information documents list sleep problems, specifically insomnia, as an adverse reaction reported during postmarketing surveillance. This is categorized as a nervous system disorder.

Q: Is Azro safe to use during pregnancy or while breastfeeding?

A: The medication is authorized for use during pregnancy only when it is clearly needed after careful consideration of the risks. Regulatory documents also confirm that the drug is excreted into breast milk in small amounts, and caution is advised for nursing mothers.

Q: What kind of patients were included in the main research studies for Azro?

A: Clinical trials used for initial drug authorization included patients with specific target conditions like community-acquired pneumonia and uncomplicated skin infections. The research also included healthy volunteers for specific pharmacokinetic and safety analyses.

Q: Is Azro the same as [Name of common alternative drug]?

A: Azro is a trade name for Azithromycin, which is an Azalide and a member of the Macrolide class of antibiotics. The Azalide subgroup differentiates it from other macrolides through a specific chemical structure that leads to a longer half-life and unique tissue distribution properties.

Q: Do you have to take Azro at the exact same time every day?

A: The regimen is typically prescribed as once-daily, reflecting the medicine's ability to maintain high tissue concentrations over an extended period. Because of this, the official label does not mandate taking the dose at a precise clock-time, unlike some medications with shorter half-lives.

Q: How long do most people stay on Azro treatment?

A: For most acute infections, official regulatory documents define the treatment course as typically spanning three to five days. There is also an authorized specific long-term regimen that may be prescribed for certain prophylactic uses, often involving once-weekly dosing.

Q: Can Azro be cut in half or crushed?

A: Unless the official prescribing information states that the tablet is scored or can be divided, it is generally recommended that it be swallowed whole to maintain the intended integrity and release of the active ingredient.

Q: Is Azro addictive or habit-forming?

A: Azro is an antibiotic and is not classified as a controlled substance with known abuse potential or habit-forming properties in official regulatory documents.

Q: What is the difference between Azro and the older class of drugs for this condition?

A: Azro's active substance is in the Azalide subgroup, which distinguishes it from older macrolide antibiotics through a unique chemical structure that results in a longer half-life and enhanced distribution into body tissues.

Q: What kind of foods or drinks should be avoided while on Azro?

A: The only required avoidance is taking the medicine with aluminum- or magnesium-containing antacids, which must be separated by at least one to two hours. Most oral tablet and suspension forms can otherwise be taken with or without food, as noted in the official instructions.

Q: If Azro helps my condition, can I stop taking it on my own?

A: Official guidance indicates that completing the full prescribed course is generally important, even if symptoms improve quickly. This is done to ensure the eradication of the targeted susceptible bacteria and to reduce the potential for developing drug-resistant bacteria.

Q: Is there a generic version of Azro available?

A: Azro is the trade name for the active ingredient Azithromycin. The active ingredient is available generically from multiple manufacturers, following regulatory approval.

How should Azro be stored and disposed of?

How to Store and Dispose of Azro (Azithromycin)

The storage and disposal requirements for Azro must strictly follow official regulatory documents to maintain drug stability and ensure safety.

Tablets and Dry Powder for Suspension:

  • Store at Controlled Room Temperature, typically 20 C to 25 C.
  • Keep the powder in the original container and tightly closed to protect it from moisture.

Constituted Oral Suspension:

  • The mixed liquid is stable for 10 days and must be stored at or below 30 C.
  • Do not refrigerate the constituted suspension.

Disposal and Child Safety:

  • The medicine must be kept out of the reach and sight of children.
  • Any unused product, particularly remaining suspension, must be discarded according to local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azro found in:

A-Z Index: